Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy
Santhera Pharmaceuticals announces that the first patient in the CALLISTO Phase I study assessing the pharmacokinetics, safety and tolerability of oral omigapil in patients with Congenital Muscular Dystrophy (CMD) has been dosed and all participating patients have been recruited. This study, which is being conducted at the US National Institutes of Health (NIH), will also evaluate the feasibility of conducting disease-relevant clinical assessments that could be used as endpoints in future efficacy trials in pediatric and adolescent CMD patients. Omigapil is a drug candidate in-licensed from Novartis and repositioned by Santhera for development in CMD.
The study is being conducted at the NIH's National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland, and will evaluate use of the compound in 20 ambulatory and non-ambulatory patients aged 5 to 16 years affected by either Ullrich or MDC1A subtypes of CMD. All patients have been selected, pre-screened and randomly assigned to one of the three study cohorts that are starting sequentially with ascending doses of omigapil. Following a 4-week vehicle run-in phase, each patient will receive one of three doses of omigapil (0.02, 0.08 or 0.2 mg/kg/day) for 12 weeks, during which period the pharmacokinetics of omigapil will be assessed as well as the patients' respiratory function, muscle strength and motor function. To ensure the collection of as much information as possible from both subtypes of CMD, Ullrich or MDC1A, all patients have been identified and randomized prior to the first dosing.
The first patient received the starting dose of 0.02 mg/kg/day, applied in a new liquid formulation developed by Santhera for this patient population. Only after an independent data and safety monitoring board (DSMB) has assessed the pharmacokinetic and safety data in each completed cohort, dosing in subsequent cohorts will follow at ascending doses. Due to the staggered dosing of patients, the study is expected to run until the end of 2016.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Tumors backfire on chemotherapy
Before retinal cells die, they regenerate, Penn vet blindness study finds
A nanofiber matrix for healing
Fundamental regulation mechanism of proteins discovered - The chemical nature of the switch was completely unknown
Three dimensional force microscopy - Method of measuring forces of tumour cells as they migrate through connective tissue developed
Emerging psoriasis therapies go head-to-head with marketed drugs - Comparative efficacy data critical for higher uptake since psoriasis is not considered a life-threatening condition
Novo Nordisk opens new research centre in Seattle
Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems
